Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

PDUFA Negotiations Begin With FDA Seeking Review System Reform

This article was originally published in The Tan Sheet

Executive Summary

During the inaugural negotiating session for renewal of PDUFA, which covers OTC switch and other nonprescription product NDAs, FDA says among its goals are “enhancements to the review processes.” The five-hour session included the ground rules for the talks and FDA and industry representatives also laid out their general wants and needs.

Advertisement

Related Content

CHPA Looks For FDA Reform Legislation To Deliver Monograph Changes In 2016
CHPA Looks For FDA Reform Legislation To Deliver Monograph Changes In 2016
PDUFA VI: BIO Survey Finds FDA Communication Problems
PDUFA Budgeting: What Will Get Added, Subtracted – Or Multiplied By Cures?
PDUFA VI: Price Tag For Patient Experience Data Validation May Go Up
‘Breakthrough’ Fee Eyed As Deterrent To Frivolous Requests

Topics

Advertisement
UsernamePublicRestriction

Register

PS107988

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel